Dr. Philip Gould FRSC, SRPharmS, C. Chem
`
`
`
`152 High Street North, Stewkley, Leighton Buzzard, Bedfordshire LU7 0EP, United Kingdom
`
`+44 (0)7718 794679
`phil@jadarapharma.com
`
`Mobile (cell) :
`
`+44(0)7802 636998
`
`
`Phone:
`E-mail:
`
`
`Profile
`
`Phil Gould is a senior pharmaceutical technical professional with extensive international ‘blue chip’ industry
`experience of drug discovery and development. He has a background in pharmaceutical development,
`pharmaceutical
`technology,
`formulations design and solid-state pharmaceutics
`(salts, hydrates,
`polymorphs, pseudopolymorphs, co-crystals etc.), based on an in depth understanding of physical
`chemistry, pharmaceutics, bio-pharmaceutics and drug design.
`
`Phil was educated with an honours degree in chemistry, a PhD in physical chemistry, and is a Chartered
`Chemist, a Fellow of the Royal Society of Chemistry, a Scientist of the Royal Pharmaceutical Society and
`honorary Professor of Pharmaceutical Sciences.
`
`Phil has published over 30 peer-reviewed papers in pharmaceutics and pharmaceutical technology, given
`over 40 seminars in the areas of pharmaceutical sciences, pharmaceutical technology, R&D strategy and
`R&D management. He has also published a book chapter in solid dosage form technology, and been an
`inventor on 4 pharmaceutical patents. Phil has been, and continues to be, a manuscript reviewer for major
`pharmaceutical scientific journals.
`Personal Information
`
`Marital status: Married
`Education
`BSc. Chemistry (Hons), University of Hull, 1975. Awarded J.J. Kipling Prize Physical Chemistry.
`
`Ph.D. Physical Chemistry, University of Hull, 1979.
`
`Business Systems: Institute of Management Development, Geneva, 1993.
`
`Honorary Professor of Industrial Pharmacy, Liverpool John Moores University.
`
`Employment Experience
`
`Current
`
`2005 - to date, Founder and CEO, Jadara Pharma Ltd – A healthcare technical & business consultancy
`with international contracts in technical expert reports (drug discovery, pharmaceutical solid-state,
`pharmaceutics, formulation and technology), non-executive services, strategic business planning, fund
`raising, patent litigation, strategic product development, product commercialisation, spin out portfolio
`management and investor support to trade sale or IPO.
`
`
`
`
`Nationality: British
`
`
`
`Place of Birth: London
`
`Philip Gould Curriculum Vitae
`
`
`
`
`Date: May 2021
`
`Apotex Exhibit 1003.001
`
`

`

`Global clients in pharma (blue chip and SMEs), biotech, medical diagnostics and medical devices as well
`as venture capital due diligence. See www.jadarapharma.com.
`
`
`Previous Experience
`
`2010 - 2014, Director - RedX Pharma Ltd – a venture backed drug discovery company focused in the
`areas of infection, oncology and cardiovascular medicine. Role as pharmaceutical development advisor
`and Chair/Co-ordinator of the Scientific Advisory Board for Anti-infective and Oncology Divisions.
`
`2007 - 2010, Director - Bradford Pharma Ltd – a venture capital backed Avecia (AZ) spin out company,
`based in the UK and focused on redox API process chemistry. Sold to RedX Pharma Ltd.
`
`2006 - 2012, Chief Business Officer - Liverpool School of Tropical Medicine – internal drug discovery
`and product development consultant, R&D collaborations for fund raising for neglected disease drug
`discovery programmes with benefactor foundations, spin out of several businesses.
`
`2003 - 2010, Director - Lectus Therapeutics Ltd - a Cambridge based small molecule drug discovery,
`company focused on ion channels to treat neuropathic pain and was a spin out from Bristol University. Sold
`to UCB Pharma. Discovery/development strategic advisor for programmes.
`
`1999 - 2000, Director - OraTol Ltd. - an oral tolerance allergy company backed by two major venture
`capital groups (Atlas and Nomura).
`
`Previous Employment History
`
`1999 - 2005 Chief Executive, Provalis plc – a dynamic diversified, LSE & NASDAQ
`listed,
`pharmaceutical and medical diagnostics company with R&D base in drug delivery &
`formulation (peptides), vaccines (respiratory) & diagnostics. Group sold
`to Galen
`(Pharmaceuticals) and BioRad (Diagnostics).
`
`1998 - 1999 Group R&D Director, Cortecs plc – Biotechnology Company with wide interests in
`vaccines, drug delivery (peptides) and diagnostics. Directed research programmes.
`
`
`1988 - 1997 Head, New Product Introduction and Product Technology, GlaxoWellcome Group
`(Now GlaxoSmithKline). Responsible for final stages of product development, technology
`transfer and product start up across a wide range of product technologies; solid dosage
`forms, steriles and parenterals and respiratory products and devices. Responsible for a wide
`range of product, process and packaging technologies.
`
`
`1985 - 1988 Senior Manager Pharmaceutical Development Group: Lederle Laboratories (now
`Wyeth/Pfizer) developing a wide range of pharmaceutical products for global markets from
`novel NCE’s and established API’s. NCE pharmaceutics, ‘development candidate’ selection
`and development of sterile, solid, semi-solid and lyophilised products.
`
`
`1980 - 1985 Principal Research Scientist: Pharmaceutical Development: Pfizer Central Research –
`API form selection, pre-formulation, formulations research, pharmaceutical technology. The
`development of a wide range of dosage forms; solid dosage, sterile liquids, lyophiles and
`also specific controlled release animal health products.
`
`
`1978 - 1980 Section Leader Drug Design: Reckitt & Colman Pharmaceutical Division –
`physicochemical profiling and lead selection of a number of NCE candidates linking to
`ADME profiling and formulations research.
`
`
`
`Philip Gould Curriculum Vitae
`
`
`
`
`Date: May 2021
`
`Apotex Exhibit 1003.002
`
`

`

`
`
`
`Professional
`Memberships
`
`
`Fellow of the Royal Society of Chemistry & RSC Chartered Chemist, 1980 –
`
`Charter Member of American Society of Pharmaceutical Scientists, 1986 -
`2020
`
`Institute for Management Development (IMD) Alumni, 1994 –
`
`Member of the Institute of Directors, 2000 – 2016.
`
`Scientific Member Royal Pharmaceutical Society, 2014 -
`
`Advisory Boards
`
`Member of IUPAC Sub-Committee on the Use of Salt Forms in Drug
`Development; 1995 - 1998.
`
`Member of GlaxoWellcome Drug Development Management Committee;
`1992 -1997.
`
`Chairmanship of GlaxoWellcome API and Product Technical Review
`Committee (Respiratory & Solid Dosage Form Products); 1995 -1997
`
`Member of Provalis Vaccine Development Advisory Board; 2000-2002.
`
`Member of Lectus Therapeutics Scientific Advisory Board on ion channels and
`accessory proteins for pain therapeutics; 2003 – 2008.
`
`Chairmanship of Anti-infectives and Oncology Scientific Advisory Boards,
`RedX Pharma Ltd; 2010 – 2013.
`
`Assessor for UK Technology Strategy Board – Driving Innovation (Infectious
`Disease Diagnostics); 2010/11.
`
`Member of ESAC for Filariasis R&D Programme, AWOL/LSTM and Bill &
`Melinda Gates Foundation Programme, 2009 – 2013.
`
`Assessor for UK Funding Programme in Life Sciences – National Biocatalyst
`Fund, Infection and vaccines; 2012.
`
`Assessor for UK Biocatalyst Fund and MediTech Fund – Peer Reviews of
`science, technology and investment potential; 2012 - to date.
`
`Biochemical Industries Association – Biotech Business mentor; 2004 - 2009.
`
`BioNow Life Science Mentor; 2013 – 2016
`
`Steering Committee Member – Pharmaceutical Investments, LSBC, Warsaw,
`Poland; 2015 – 2016
`
`
`Pharmaceutical assessor; Innovate UK and UK Newton Fund 2016 – to date.
`
`Precision Medicine Investment assessor, Innovate UK 2018 -
`
`
`
`Philip Gould Curriculum Vitae
`
`
`
`
`Date: May 2021
`
`Apotex Exhibit 1003.003
`
`

`

`
`
`
`
`
`
`
`Publications, Seminars, Books, Patents
`
` A
`
` series of scientific papers have been published, and seminars given in the areas of pharmaceutics,
`formulation research, drug salt form selection, solid state hydrates, the use of co-solvents, pharmaceutical
`technology, respiratory product design, tablet formulation, controlled release dosage forms, formulation
`optimisation and technology transfer.
`
`Phil continues to give seminars in the areas of physical pharmacy and formulation, and on the business
`mechanics of drug development. He has also been a manuscript reviewer for the American Chemical
`Society and for the journals: ‘Journal of Pharmaceutical Sciences’, ‘Drug Development and Industrial
`Pharmacy’ and ‘Crystal Growth and Design’.
`
`Pharmaceutical Expert
`
`Phil has been a pharmaceutical expert on a number of patent litigation disputes that have related to
`pharmaceutical salt forms, pharmaceutical formulation, pharmaceutical pro-drugs and a wide variety of
`pharmaceutical technology. He has dealt with a number of cases for both innovator and generic companies
`in the USA and EU, and has made declarations on behalf of companies with regulatory authorities. He has
`been deposed for evidence a number of times (>20).
`
`Patent Litigation, Depositions and Testimony in the Last Four Years
`
`No depositions or trial testimony have been given in the last four years; (May 2017- May 2021).
`
`
`
`
`
`
`Philip Gould Curriculum Vitae
`
`
`
`
`Date: May 2021
`
`Apotex Exhibit 1003.004
`
`